1,3-dihydroxypropan-2-yl (5Z,8Z,11E,14E)-icosa-5,8,11,14-tetraenoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 内源性大麻素
• 英文名称: 1,3-dihydroxypropan-2-yl (5Z,8Z,11E,14E)-icosa-5,8,11,14-tetraenoate
• 化学式: C₂₃H₃₈O₄
• 分子量: 378.5
• InChiKey: RCRCTBLIHCHWDZ-BJCBFJDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  27
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US20160256429A1

  公开（公告）日：2016-09-08

  The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and/or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and/or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and/or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and/or treating a pathological condition selected from metabolic syndrome and/or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.
• COMPOUNDS, COMPOSITIONS AND CORRESPONDING USES FOR PREVENTING AND/OR TREATING OF DYSLIPIDEMIA
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：US20160287542A1

  公开（公告）日：2016-10-06

  The present invention relates to the field of medicine. It relates more particularly to the use of compounds to prevent and/or treat lipotoxicity in a subject, especially lipotoxicity by hypoxia. The invention relates more particularly to compositions, especially pharmaceuticals compositions and nutritional supplements or complements comprising such compounds as well as their use to prevent and/or treat lipotoxicity, especially lipotoxicity by hypoxia. The compounds and compositions of the invention can especially be advantageously used to prevent and/or treat a pathology from among pulmonary pathologies, especially cystic fibrosis or a chronic obstructive pulmonary disease.
• US9821000B2
  申请人：——

  公开号：US9821000B2

  公开（公告）日：2017-11-21